Erenumab (Aimovig) prior authorization at Point32Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Point32Health requires prior-authorization documentation for Erenumab (Aimovig): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Point32Health reviews Erenumab (Aimovig) prior authorizations against its medical policy . Point32Health-specific context: Formed by 2021 merger of Tufts Health Plan and Harvard Pilgrim Health Care; ~2M members across New England. Brands operate separately (Harvard Pilgrim, Tufts Health Plan). MA DOI primary regulator; MA OPP external review applies in Massachusetts.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Point32Health's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy)
- MA mandated benefit disputes
- Specialty drug PA
- Behavioral health prior auth
Erenumab (Aimovig)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring multiple older preventives
- Migraine days threshold (e.g., ≥4/month)
Brand: Aimovig. First CGRP receptor monoclonal antibody for migraine prevention.
Manufacturer patient-assistance program: Aimovig Co-Pay Card — relevant when a Point32Health denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.point32health.org/providers) with the same packet plus an applicable, current clinical source supporting Erenumab (Aimovig)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Point32Health denial on DenialHelp.
Contact Point32Health
- Provider portal: https://www.point32health.org/providers
Frequently asked questions
What documentation does Point32Health need for Erenumab (Aimovig) prior auth?
Point32Health's typical PA packet for Erenumab (Aimovig): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Point32Health?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Erenumab (Aimovig) at Point32Health?
Preparation scenarios to check against the current notice and policy include: Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy); MA mandated benefit disputes; Specialty drug PA. These are not measured frequency claims. For Erenumab (Aimovig), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Point32Health on Erenumab (Aimovig)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Erenumab (Aimovig) PA packet
Open ApprovalHelp — generate a Erenumab (Aimovig) prior-auth packet tailored to Point32Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com